PATENT CLAIM ANALYSIS

Application Number: 15882620
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "252010"]

Abstract:
Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.

Claim (Index 3):
The compound of  claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 4  is hydrogen and R 5  is fluoro.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.45283
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15328813', '15749652', '15108903', '10992146', '15768953']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.763372706533283
- 35 USC 102 Novelty (BERT): 0.56215006511736
- Combined Prediction Score: 0.7432504423916908
- Mean Citation Score: 320.877984
- Max Citation Score: 436.5513
- Similarity Product: 318.52487726840974

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test